Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab single-arm phase 2 study in pyoderma gangrenosum
2015-000762-65Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab in pyoderma gangrenosum (PG), sponsored by Technical University of Munich. Primary endpoint: Change in Physician's Global Assessment of the target lesion. Started Jun 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on 2015-000762-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000762-65.